1. Immobilized TIGIT Dimer Protein, Human, Recombinant (Avi & His), Biotinylated (Cat#TMPY-07044）at 2 μg/mL (100 μL/well) on streptavidin precoated (2 μg/mL, 100 μL/well) can bind CD155/PVR Protein, Human, Recombinant (hFc) (Cat#TMPY-00699), the EC50 is 15-45 ng/mL. 2. Immobilized Anti-Tigit Antibody, Human IgG1 (Tiragolumab) at 2 μg/mL (100 μL/well) can bind TIGIT Dimer Protein, Human, Recombinant (Avi & His), Biotinylated (Cat#TMPY-07044), the EC50 is 0.5-1.5 ng/mL (Routinely tested).

TIGIT, also known as V-set and transmembrane domain-containing protein 3 (VSTM3) or V-set and immunoglobulin domain-containing protein 9 (VSIG9) is a new surface protein containing an immunoglobulin variable domain, a transmembrane domain and an immunoreceptor tyrosine-based inhibitory motif (ITIM). TIGIT is expressed on regulatory, memory, activated T cells and NK cells. It binds PVR with high affinity, and PVRL2 with lower affinity, but not PVRL3. Knockdown of TIGIT with siRNA in human memory T cells did not affect T cell responses, however, TIGIT inhibits NK cytotoxicity directly through its ITIM. TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. The binding of PVR to TIGIT on human dendritic cells enhanced the production of IL-1 and diminished the production of IL-12p4. Also, TIGIT counter inhibits the NK-mediated killing of tumor cells and protects normal cells from NK-mediated cytotoxicity thus providing an "alternative self" mechanism for MHC class I inhibition.Cancer ImmunotherapyCo-inhibitory Immune Checkpoint TargetsImmune CheckpointImmune Checkpoint TargetsImmunotherapyTargeted Therapy

≥ 95% as determined by SDS-PAGE. ≥ 95% as determined by SEC-HPLC.